Appointment underscores Ashfield’s commitment to its Medical Science Liaison offering

Glen E. Martin was appointed as senior vice president, medical sciences. In assuming this position, Glen takes on the task of heading Ashfield’s growing Medical Science Liaison (MSL) service offering to clients throughout the United States and Canada.

Glen-Martin-WEBThis addition of MSL programs to Ashfield’s comprehensive commercial and medical services portfolio responds to the increasing demand within the pharmaceutical industry to provide healthcare professionals with greater value. Due to their advanced scientific training, MSLs are able to discuss the most complex scientific and medical information, bringing a level of expertise and authority to complement the work done by traditional medical sales representatives with healthcare professionals.

Under Glen, the medical sciences team will focus on initial Medical Science Liaison program design and development, recruitment and sourcing, skills and scientific training and overall program management. Julian is now responsible for Ashfield’s contract sales, nursing and contact centre teams across 22 countries.Ashfield will provide the requisite operational backbone, drawing upon its experience in recruiting, human resources, legal, compliance services and field and contact-center based employee support.

As one of the largest US and UK providers of field nurses in the industry, we will bring the same level of exceptional talent and innovation in expanding our offering of MSLs to our clients both in the field and in our call center,” remarks Mary Anne Greenberg, President of Ashfield Medical Information and Pharmacovigilance. “Ashfield’s ability to integrate content from our medical communications experts with MSLs in the field and PharmDs staffed in our call center, provides clients the flexibility needed for a fast, evolving marketplace.”

Glen brings over 22 years of experience in the healthcare and pharmaceutical industry in various leadership roles to his new position. Prior to joining Ashfield, he was Executive Director for Celgene where he successfully managed the strategic planning and business operations of the U.S. Medical Affairs Division, while also leading the Clinical Operations Team. Prior to this, Glen held positions as the Senior Director Disease Registry Program and the National Director of MSL’s at Celgene. In addition, Glen has spent 14 years on the commercial side of the pharmaceutical/biotechnology industry, most recently as Vice President of Oncology Sales at Coves Pharma.

Adding MSL capabilities to Ashfield’s portfolio is a logical extension of its clinical and medical services,” remarks Glen. “The increasing need for MSL programs in the marketplace is clear, and with this new service offering we continue to enhance Ashfield as a best-in-class organization, while delivering a superior solution for our clients.”